By Finance Pulse in Transformative —

D. Boral Capital Starts Avita Medical at Buy with $25 Target

D. Boral Capital initiates coverage on Avita Medical (RCEL) with a Buy rating and $25 target, citing promising clinical results in biotechnology.

A sleek, modern image featuring a stylized DNA helix and financial charts, symbolizing the intersect
D. Boral Capital Starts Avita Medical at Buy with $25 Target

D. Boral Capital initiated coverage of Avita Medical (RCEL) with a Buy rating and $25 price target, noting promising clinical results.

Source